Skip to content

Docrates Cancer Center becomes part of Mehiläinen

16.5.2024 Categories: Press releases
Docrates Cancer Center, which specialises in the diagnostics, treatment and monitoring of cancer, becomes part of Mehiläinen through an acquisition signed on 16 May 2024. The strong development of Docrates' operations and the provision of high-quality cancer treatments to both Finnish and international customers will continue going forward. The transaction requires the approval of the competition authorities in order to take place.

At Docrates Cancer Center, people with cancer receive individualised service under one roof throughout the entire treatment and monitoring period. The company’s operations emphasise individual cancer treatments with no delay, as well as high quality, education and research. Docrates has a hospital in Helsinki, where more than 130 cancer treatment professionals provide services. As a private cancer hospital, Docrates is a pioneer in Europe and the only one of its kind in the Nordic countries.  In addition to Finland, people seek Docrates’ services from up to 50 different countries each year, including Sweden and Norway. Docrates now becomes part of Mehiläinen through the acquisition.

“We are very excited to continue to develop high-quality cancer treatment services together with Docrates. As a pioneer in cancer treatment, Docrates has built a unique treatment center on both Finnish and international standards and wants to maintain the latest research and treatment methods in its operations. At Mehiläinen, we want to serve our customers holistically and to offer a high-quality treatment chain for cancer as well. This is now possible for us through Docrates Cancer Center”, says Janne-Olli Järvenpää, CEO of Mehiläinen Group.

“For 15 years, we have been proud to build and support Docrates’ success story as an international, state-of-the-art cancer hospital. This pioneering journey has been amazing. For Docrates, the next natural step in the development of our operations is internationalisation. We are convinced that Mehiläinen’s strong domestic traditions and current international organisation will provide the right home for Docrates for the next phase of growth. In my opinion, Finland now needs precisely these kinds of initiatives that enable innovative pioneering companies to internationalise, grow and employ. The Aava Terveyspalvelut group is a strong national player in the field of healthcare, and in future we will focus on developing the business of Lääkärikeskus Aava, Pikkujätti and Aisti Health”, says Antti Aho, CEO of Docrates’ former largest owner, Aava Terveyspalvelut Oy.

“Through its extensive network and resources, Mehiläinen gives Docrates the opportunity to offer the latest cancer diagnostics and treatments to an increasingly large customer group, both in Finland and in other countries. We plan to, for instance, open a new clinic in Stockholm. I also believe that Docrates’ strong approach of “people standing by people” fits perfectly with Mehiläinen’s long-established traditional Finnish corporate culture”, says Ilpo Tolonen, CEO of Docrates.

In future, Docrates and Mehiläinen will continue their joint investments in improving service quality, expanding their operations and educating and training specialists. The aim is for Docrates to continue its strong research work and provide cancer treatments based on the latest research to its customers.

In future, Mehiläinen’s comprehensive service network will give customers even smoother access to services. With Mehiläinen, it’s possible to offer customers more extensive rehabilitation-supporting physiotherapy, mental health support and other forms of therapy. Mehiläinen’s international organisation and capabilities gives broader resources to grow operations, even outside of Finland.

Docrates’ operations will continue as before at the company’s hospital in Ruoholahti, Helsinki. Docrates’ employees and professionals will continue as old employees and private practitioners with their previous contracts after the acquisition. The transaction requires the approval of the competition authorities in order to take place.

Further information:

Mehiläinen Group, CEO Janne-Olli Järvenpää.
Contacts via Laura Martinsuo, Communications, Mehiläinen, tel. +358 (0)40 196 2892,

Docrates Cancer Center, CEO Ilpo Tolonen,, tel. +358 (0)50 500 1880

Mehiläinen Group is a well-known and appreciated private provider of social and health care services offering high-quality, comprehensive services in Finland and abroad. Now 114 years old, Mehiläinen is a rapidly developing and growing forerunner in its sector. The company invests in the opportunities offered by digitalisation and in the effectiveness and quality of care in all its business areas. Mehiläinen serves 2.1 million customers annually and provides services by more than 37,000 employees and private practitioners in its 840 offices and clinics. Internationally, Mehiläinen offers healthcare services in Sweden, Germany and Estonia, as well as digital healthcare software solutions through its subsidiary BeeHealthy.

Docrates Cancer Center is an international hospital in Helsinki specialising in cancer treatment. We provide individual services for cancer patients throughout the treatment chain, from diagnostics to post-treatment follow-up. After diagnosis and imaging, treatment can be planned and initiated without delay. Our unique concept attracts patients from all over the world. We have treated patients from more than 60 different countries. Together with our network of leading clinical experts, we provide genuinely individual state-of-the-art cancer treatment services. One step ahead – with people standing by people.


Lue lisää

Verification of identification

Please be prepared to present an identity document when you register at the reception.

Read more

Investments in diagnostics, cancer treatment and services – Docrates Cancer Center published its 2023 annual review

In 2023, Docrates Cancer Center promoted its strategy by investing in larger facilities, developing services related to the early detection...

Customer infoletter 21, May 2024

Docrates Cancer Center becomes part of Mehiläinen through an acquisition signed on 16 May 2024. The transaction requires the approval...

Promising preliminary outcomes from stereotactic radiotherapy for kidney cancer

In Finland, about 1,000 people are diagnosed with kidney cancer each year. Up to half of these are found by...

Why come to Docrates Cancer Center?

  • Top cancer experts and effective treatments without delay.
  • Individual care. You have your own care team - your doctor and your nurse.
  • Front line cancer treatment. Latest medical technology combined with proven expertise in cancer care.
  • Experience in treating international patients from over 60 countries. Multilingual personnel.
+358 10 773 2010

Contact us!

Mon-Thu 8:00-18:00, Fri 8:00-16:00